This HTML5 document contains 112 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n16http://www.rxlist.com/cgi/generic3/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n9http://linked.opendata.cz/resource/drugbank/drug/DB00988/identifier/national-drug-code-directory/
n7http://linked.opendata.cz/resource/drugbank/company/
n18http://linked.opendata.cz/resource/mesh/concept/
foafhttp://xmlns.com/foaf/0.1/
n25http://linked.opendata.cz/resource/drugbank/dosage/
n23http://linked.opendata.cz/resource/drugbank/drug/DB00988/identifier/chemspider/
n19http://linked.opendata.cz/resource/drugbank/drug/DB00988/identifier/chebi/
n27http://bio2rdf.org/drugbank:
n30http://linked.opendata.cz/resource/drugbank/drug/DB00988/identifier/wikipedia/
admshttp://www.w3.org/ns/adms#
n14http://linked.opendata.cz/resource/drugbank/drug/DB00988/identifier/pharmgkb/
n12http://linked.opendata.cz/resource/drugbank/drug/DB00988/identifier/kegg-compound/
n31http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n10http://linked.opendata.cz/resource/drugbank/drug/DB00988/identifier/pdb/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n22http://linked.opendata.cz/resource/drugbank/medicinal-product/
n15http://linked.opendata.cz/resource/drugbank/drug/DB00988/identifier/pubchem-compound/
n17http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n6http://www.drugs.com/cdi/
n4http://linked.opendata.cz/resource/drugbank/property/
n13http://linked.opendata.cz/resource/drugbank/drug/DB00988/identifier/pubchem-substance/
xsdhhttp://www.w3.org/2001/XMLSchema#
n24http://linked.opendata.cz/resource/drugbank/drug/DB00988/identifier/drugbank/
n11http://linked.opendata.cz/resource/drugbank/drug/DB00988/identifier/iuphar/
n28http://linked.opendata.cz/ontology/sukl/drug/
n29http://linked.opendata.cz/resource/atc/
n21http://linked.opendata.cz/resource/drugbank/drug/DB00988/identifier/guide-to-pharmacology/

Statements

Subject Item
n2:DB00988
rdf:type
n3:Drug
n3:description
One of the catecholamine neurotransmitters in the brain. It is derived from tyrosine and is the precursor to norepinephrine and epinephrine. Dopamine is a major transmitter in the extrapyramidal system of the brain, and important in regulating movement. A family of receptors (receptors, dopamine) mediate its action. [PubChem]
n3:dosage
n25:271B4A47-363D-11E5-9242-09173F13E4C5 n25:271B4A48-363D-11E5-9242-09173F13E4C5 n25:271B4A49-363D-11E5-9242-09173F13E4C5 n25:271B4A4A-363D-11E5-9242-09173F13E4C5 n25:271B4A4B-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Barron AB, Maleszka R, Vander Meer RK, Robinson GE: Octopamine modulates honey bee dance behavior. Proc Natl Acad Sci U S A. 2007 Jan 30;104(5):1703-7. Epub 2007 Jan 19. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17237217 # Giuliano F, Allard J: Dopamine and male sexual function. Eur Urol. 2001 Dec;40(6):601-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11805404 # Giuliano F, Allard J: Dopamine and sexual function. Int J Impot Res. 2001 Aug;13 Suppl 3:S18-28. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11477488 # Berridge KC, Robinson TE: What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience? Brain Res Brain Res Rev. 1998 Dec;28(3):309-69. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/9858756 # Pecina S, Cagniard B, Berridge KC, Aldridge JW, Zhuang X: Hyperdopaminergic mutant mice have higher "wanting" but not "liking" for sweet rewards. J Neurosci. 2003 Oct 15;23(28):9395-402. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/14561867
n3:group
approved
n3:halfLife
2 minutes
n3:indication
For the correction of hemodynamic imbalances present in the shock syndrome due to myocardial infarction, trauma, endotoxic septicemia, open-heart surgery, renal failure, and chronic cardiac decompensation as in congestive failure
n3:manufacturer
n7:271B4A3E-363D-11E5-9242-09173F13E4C5 n7:271B4A3F-363D-11E5-9242-09173F13E4C5 n7:271B4A3C-363D-11E5-9242-09173F13E4C5 n7:271B4A3D-363D-11E5-9242-09173F13E4C5 n7:271B4A42-363D-11E5-9242-09173F13E4C5 n7:271B4A43-363D-11E5-9242-09173F13E4C5 n7:271B4A40-363D-11E5-9242-09173F13E4C5 n7:271B4A41-363D-11E5-9242-09173F13E4C5 n7:271B4A3A-363D-11E5-9242-09173F13E4C5 n7:271B4A3B-363D-11E5-9242-09173F13E4C5 n7:271B4A38-363D-11E5-9242-09173F13E4C5 n7:271B4A39-363D-11E5-9242-09173F13E4C5
owl:sameAs
n27:DB00988 n31:DB00988
dcterms:title
Dopamine
adms:identifier
n9:0517-1805-25 n10:LDP n11:940 n12:C03758 n13:46506043 n14:PA449396 n15:681 n19:18243 n21:940 n23:661 n24:DB00988 n30:Dopamine
n3:mechanismOfAction
Dopamine is a precursor to norepinephrine in noradrenergic nerves and is also a neurotransmitter in certain areas of the central nervous system. Dopamine produces positive chronotropic and inotropic effects on the myocardium, resulting in increased heart rate and cardiac contractility. This is accomplished directly by exerting an agonist action on beta-adrenoceptors and indirectly by causing release of norepinephrine from storage sites in sympathetic nerve endings. In the brain, dopamine actas as an agonist to the five dopamine receptor subtypes (D!, D2, D3, D4, D5).
n3:packager
n7:271B4A2F-363D-11E5-9242-09173F13E4C5 n7:271B4A30-363D-11E5-9242-09173F13E4C5 n7:271B4A31-363D-11E5-9242-09173F13E4C5 n7:271B4A32-363D-11E5-9242-09173F13E4C5 n7:271B4A33-363D-11E5-9242-09173F13E4C5 n7:271B4A36-363D-11E5-9242-09173F13E4C5 n7:271B4A37-363D-11E5-9242-09173F13E4C5 n7:271B4A34-363D-11E5-9242-09173F13E4C5 n7:271B4A35-363D-11E5-9242-09173F13E4C5
n3:routeOfElimination
It has been reported that about 80% of the drug is excreted in the urine within 24 hours, primarily as HVA and its sulfate and glucuronide conjugates and as 3,4-dihydroxyphenylacetic acid. A very small portion is excreted unchanged.
n3:synonym
Dopaminum 4-(2-Aminoethyl)pyrocatechol Dopamin Oxytyramine 4-(2-Aminoethyl)benzene-1,2-diol 3,4-Dihydroxyphenethylamine Hydroxytyramin 3-Hydroxytyramine 2-(3,4-Dihydroxyphenyl)ethylamine 4-(2-Aminoethyl)-1,2-benzenediol Hydroxytyramine Dopamine 4-(2-Aminoethyl)catechol Dophamine Dopamina Deoxyepinephrine
n3:toxicity
LD<sub>50</sub> oral mice = 1460 mg/kg, LD<sub>50</sub> oral rats = 1780 mg/kg. Spasm or closing of eyelids, nausea, vomiting, cardiac arrhythmias, involuntary movements of the body including the face, tongue, arms, hand, head, and upper body; hypotension, haemolytic anaemia, urinary retention, duodenal ulcer, sialorrhea, ataxia, abdominal pain, dry mouth, nightmares, tachypnoea, bruxism, confusion, and insomnia.
n3:proteinBinding
No information currently available on protein binding.
n3:salt
n3:synthesisReference
Klaus Schoellkopf, Rudolf Albrecht, Manfred Lehmann, Gertrud Schroeder, "Novel dopamine derivatives, processes for their preparation, and their use as medicinal agents." U.S. Patent US4958026, issued February, 1972.
n17:hasConcept
n18:M0006756
foaf:page
n6:dopamine.html n16:dopamine.htm
n3:IUPAC-Name
n4:271B4A50-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B4A56-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B4A55-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B4A52-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B4A53-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B4A54-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B4A66-363D-11E5-9242-09173F13E4C5 n4:271B4A4E-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B4A4F-363D-11E5-9242-09173F13E4C5 n4:271B4A4C-363D-11E5-9242-09173F13E4C5 n4:271B4A69-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B4A4D-363D-11E5-9242-09173F13E4C5
n3:pKa
n4:271B4A6B-363D-11E5-9242-09173F13E4C5
n28:hasATCCode
n29:C01CA04
n3:H-Bond-Acceptor-Count
n4:271B4A5C-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B4A5D-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B4A57-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B4A58-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B4A5A-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B4A59-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B4A5B-363D-11E5-9242-09173F13E4C5
n3:absorption
Dopamine is rapidly absorbed from the small intestine.
n3:affectedOrganism
Humans and other mammals
n3:caco2-Permeability
n4:271B4A6A-363D-11E5-9242-09173F13E4C5
n3:casRegistryNumber
51-61-6
n3:category
n3:containedIn
n22:271B4A45-363D-11E5-9242-09173F13E4C5 n22:271B4A46-363D-11E5-9242-09173F13E4C5 n22:271B4A44-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B4A62-363D-11E5-9242-09173F13E4C5
n3:Boiling-Point
n4:271B4A68-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B4A64-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B4A65-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B4A67-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B4A61-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B4A60-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B4A63-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B4A51-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B4A5E-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B4A5F-363D-11E5-9242-09173F13E4C5